News
MyChesCo on MSN1h
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast CancerPositive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...
Top decision-makers from across the biopharma ecosystem will convene in Chicago for the 2nd BioCentury Grand Rounds – U.S., at the intersection of research, investment and drug development. Designed ...
MedPage Today on MSN22h
Backup Drug Gains Footing for Resistant HypertensionA mineralocorticoid receptor antagonist that blocks excess aldosterone and reduces fluid volumes, spironolactone is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback